JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
126.16 USD
-2.3 (-1.79%)
126.16 USD
0 (0%)
Overall JAZZ gets a fundamental rating of 4 out of 10. We evaluated JAZZ against 195 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
JAZZ had positive earnings in the past year.
In the past year JAZZ had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
In the past 5 years JAZZ always reported a positive cash flow from operatings.
1.2 Ratios
JAZZ has a better Return On Assets (-3.70%) than 73.98% of its industry peers.
The Return On Equity of JAZZ (-10.92%) is better than 73.98% of its industry peers.
JAZZ has a Return On Invested Capital of 5.47%. This is amongst the best in the industry. JAZZ outperforms 82.65% of its industry peers.
The Average Return On Invested Capital over the past 3 years for JAZZ is significantly below the industry average of 15.28%.
The 3 year average ROIC (3.85%) for JAZZ is below the current ROIC(5.47%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROIC | 5.47% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
JAZZ has a better Operating Margin (15.03%) than 85.71% of its industry peers.
In the last couple of years the Operating Margin of JAZZ has declined.
Looking at the Gross Margin, with a value of 88.71%, JAZZ belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
Compared to 5 years ago, JAZZ has more shares outstanding
The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.36, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.36, JAZZ is in the better half of the industry, outperforming 62.24% of the companies in the same industry.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
JAZZ has a better Debt to FCF ratio (4.33) than 85.71% of its industry peers.
A Debt/Equity ratio of 1.17 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a Debt to Equity ratio of 1.17. This is in the lower half of the industry: JAZZ underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.36 |
ROIC/WACC0.81
WACC6.72%
2.3 Liquidity
JAZZ has a Current Ratio of 1.62. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.62, JAZZ is not doing good in the industry: 65.31% of the companies in the same industry are doing better.
JAZZ has a Quick Ratio of 1.37. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.37, JAZZ is doing worse than 64.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
The earnings per share for JAZZ have decreased strongly by -62.78% in the last year.
JAZZ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.47% yearly.
Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.52% in the last year.
JAZZ shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.48% yearly.
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 6.88% on average per year.
The Revenue is expected to grow by 6.33% on average over the next years.
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.88%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.83%
Revenue Next 5Y6.33%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
JAZZ is valuated rather expensively with a Price/Earnings ratio of 19.00.
Based on the Price/Earnings ratio, JAZZ is valued cheaper than 83.16% of the companies in the same industry.
When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (27.30), we can say JAZZ is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 5.73, the valuation of JAZZ can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 95.92% of the companies listed in the same industry.
JAZZ is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19 | ||
| Fwd PE | 5.73 |
4.2 Price Multiples
90.31% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
95.41% of the companies in the same industry are more expensive than JAZZ, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.17 | ||
| EV/EBITDA | 8.45 |
4.3 Compensation for Growth
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.48
EPS Next 2Y1.92%
EPS Next 3Y4.78%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
126.16
-2.3 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners102.03%
Inst Owner Change3.14%
Ins Owners2.44%
Ins Owner Change0.97%
Market Cap7.65B
Analysts84.8
Price Target190.45 (50.96%)
Short Float %9.57%
Short Ratio7.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.5%
Min EPS beat(2)-64.64%
Max EPS beat(2)-6.35%
EPS beat(4)2
Avg EPS beat(4)-10.46%
Min EPS beat(4)-64.64%
Max EPS beat(4)17.85%
EPS beat(8)3
Avg EPS beat(8)-9.87%
EPS beat(12)4
Avg EPS beat(12)-16.71%
EPS beat(16)7
Avg EPS beat(16)-10.46%
Revenue beat(2)0
Avg Revenue beat(2)-6.37%
Min Revenue beat(2)-10.66%
Max Revenue beat(2)-2.09%
Revenue beat(4)1
Avg Revenue beat(4)-3.07%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.73%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)3
Avg Revenue beat(16)-2.09%
PT rev (1m)0.35%
PT rev (3m)0.86%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)-2.25%
EPS NY rev (1m)10.13%
EPS NY rev (3m)4.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19 | ||
| Fwd PE | 5.73 | ||
| P/S | 1.87 | ||
| P/FCF | 6.17 | ||
| P/OCF | 5.82 | ||
| P/B | 2.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.45 |
EPS(TTM)6.64
EY5.26%
EPS(NY)22.01
Fwd EY17.45%
FCF(TTM)20.44
FCFY16.2%
OCF(TTM)21.69
OCFY17.2%
SpS67.37
BVpS61.1
TBVpS-47.92
PEG (NY)N/A
PEG (5Y)3.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| ROCE | 6.92% | ||
| ROIC | 5.47% | ||
| ROICexc | 6.73% | ||
| ROICexgc | 82.21% | ||
| OM | 15.03% | ||
| PM (TTM) | N/A | ||
| GM | 88.71% | ||
| FCFM | 30.34% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexcg growth 3Y32.25%
ROICexcg growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.17 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.37 | ||
| Cap/Depr | 11.29% | ||
| Cap/Sales | 1.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.28% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 1.36 |
F-Score5
WACC6.72%
ROIC/WACC0.81
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.78%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%-255.66%
EPS Next Y-74.75%
EPS Next 2Y1.92%
EPS Next 3Y4.78%
EPS Next 5Y6.88%
Revenue 1Y (TTM)4.52%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%2.14%
Revenue Next Year4.32%
Revenue Next 2Y5.24%
Revenue Next 3Y5.83%
Revenue Next 5Y6.33%
EBIT growth 1Y-0.29%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-55.43%
EBIT Next 3Y5.37%
EBIT Next 5Y7.57%
FCF growth 1Y25.59%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y-4.47%
OCF growth 3Y21.49%
OCF growth 5Y12.45%